SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

8/10/21 5:02:22 PM ET

$PCSA

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PCSA alert in real time by email

SC 13G/A 1 d8919322_13g-a.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Processa Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

74275C205

(CUSIP Number)

August 4, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[X] Rule 13d-1(c)

[_] Rule 13d-1(d)

__________

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No

74275C205

1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	Manchester Explorer, L.P.

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	142,427

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	142,427

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	142,427

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0.9%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	PN

CUSIP No.

74275C205


1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	Manchester Management Company, LLC

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	142,427

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	142,427

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	142,427

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0.9%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	OO

CUSIP No.

74275C205


1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	Manchester Management PR, LLC

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	Puerto Rico

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	142,427

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	142,427

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	142,427

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0.9%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) OO

CUSIP No.

74275C205


1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	JEB Partners, L.P.

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	0

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	0

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	0

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	OO

CUSIP No.

74275C205


1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	James E. Besser

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	142,427

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	142,427

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	142,427

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0.9%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	IN

CUSIP No.

74275C205


1.	NAME OF REPORTING PERSONS
	I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

	Morgan C. Frank

2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
		(a) [_]
		(b) [_]

3.	SEC USE ONLY



4.	CITIZENSHIP OR PLACE OF ORGANIZATION

	United States of America

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5.	SOLE VOTING POWER

	0

6.	SHARED VOTING POWER

	142,427

7.	SOLE DISPOSITIVE POWER

	0

8.	SHARED DISPOSITIVE POWER

	142,427

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

	142,427

10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
	EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)	[_]


11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

	0.9%

12.	TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

	IN

CUSIP No.

74275C205


Item 1.	(a).	Name of Issuer:

		Processa Pharmaceuticals, Inc.

	(b).	Address of issuer's principal executive offices:

		7380 Coca Cola Drive, Suite 106 Hanover, MD 21076

Item 2.	(a).	Names of persons filing:

		Manchester Explorer, L.P. Manchester Management Company, LLC Manchester Management PR, LLC JEB Partners, L.P. James E. Besser Morgan C. Frank

	(b).	Address or principal business office or, if none, residence:

		Manchester Explorer, L.P. c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America Manchester Management PR, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America JEB Partners, L.P. 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America James E. Besser c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America Morgan C. Frank c/o Manchester Management Company, LLC 2 Calle Candina, #1701 San Juan, Puerto Rico, 00907 United States of America

	(c).	Citizenship:

		Manchester Explorer, L.P. – Delaware limited partnership Manchester Management Company, LLC – Delaware limited liability company Manchester Management PR, LLC - Puerto Rico limited liability company JEB Partners, L.P. – Delaware limited partnership James E. Besser – United States of America Morgan C. Frank – United States of America

	(d).	Title of class of securities:

		Common Stock, $0.0001 par value per share

	(e).	CUSIP No.:

		74275C205

Item 3.	If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

	(a)		[_]	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
	(b)		[_]	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
	(c)		[_]	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
	(d)		[_]	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
	(e)		[_]	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
	(f)		[_]	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)		[_]	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
	(h)		[_]	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
	(i)		[_]	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
	(j)		[_]	A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
	(k)		[_]	Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


Item 4.		Ownership.

		Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


	(a)	Amount beneficially owned:

		Manchester Explorer, L.P. – 142,427 Manchester Management Company, LLC - 142,427 Manchester Management PR, LLC – 142,427 JEB Partners, L.P. – 0 James E. Besser – 142,427 Morgan C. Frank – 142,427

	(b)	Percent of class:

		Manchester Explorer, L.P. – 0.9% Manchester Management Company, LLC – 0.9% Manchester Management PR, LLC – 0.9% JEB Partners, L.P. – 0% James E. Besser – 0.9% Morgan C. Frank – 0.9%

(c)	Number of shares as to which the person has:

	(i)	Sole power to vote or to direct the vote

		Manchester Explorer, L.P. - 0
		Manchester Management Company, LLC – 0
		Manchester Management PR, LLC - 0
		JEB Partners, L.P. – 0
		James E. Besser – 0
		Morgan C. Frank – 0
	(ii)	Shared power to vote or to direct the vote

		Manchester Explorer, L.P. – 142,427
		Manchester Management Company, LLC – 142,427
		Manchester Management PR, LLC – 142,427
		JEB Partners, L.P. – 0
		James E. Besser – 142,427
		Morgan C. Frank –142,427

		(iii)	Sole power to dispose or to direct the disposition of

			Manchester Explorer, L.P. – 0
			Manchester Management Company, LLC – 0
			Manchester Management PR, LLC - 0
			JEB Partners, L.P. – 0
			James E. Besser – 0
			Morgan C. Frank – 0
		(iv)	Shared power to dispose or to direct the disposition of

			Manchester Explorer, L.P. – 142,427
			Manchester Management Company, LLC – 142,427
			Manchester Management PR, LLC – 142,427
			JEB Partners, L.P. – 0
			James E. Besser – 142,427
			Morgan C. Frank – 142,427

Item 5.	Ownership of Five Percent or Less of a Class.

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].


Item 6.	Ownership of More Than Five Percent on Behalf of Another Person.

	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
	N/A


Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

	If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

	N/A

Item 8.	Identification and Classification of Members of the Group.

	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

	N/A

Item 9.	Notice of Dissolution of Group.

	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

	N/A

Item 10.	Certification.

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	August 10, 2021
	(Date)

	MANCHESTER EXPLORER, L.P.*

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member of the General Partner
	(Name/Title)

	Manchester Management Company, LLC*

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member
	(Name/Title)

	Manchester Management PR, LLC*

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member
	(Name/Title)


	JAMES E. BESSER

	/s/ James E. Besser
	(Signature)

	MORGAN C. FRANK

	/s/ Morgan C. Frank
	(Signature)

* The Reporting Person disclaims beneficial ownership in the common stock reported herein except to the extent of his pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

Exhibit A

AGREEMENT

The undersigned agree that this amendment number one to Schedule 13G, dated August 10, 2021, relating to the Common Stock, $0.0001 par value per share, of Processa Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

	August 10, 2021
	(Date)

	MANCHESTER EXPLORER, L.P.

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member of the General Partner
	(Name/Title)

	Manchester Management Company, LLC

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member
	(Name/Title)

	Manchester Management PR, LLC

	/s/ James E. Besser
	(Signature)

	James E. Besser, Managing Member
	(Name/Title)


	JAMES E. BESSER

	/s/ James E. Besser
	(Signature)

	MORGAN C. FRANK

	/s/ Morgan C. Frank
	(Signature)

Get the next $PCSA alert in real time by email

Date	Price Target	Rating	Analyst
4/25/2024	$8.00	Buy	H.C. Wainwright
8/3/2021	$20.00	Outperform	Oppenheimer
8/2/2021	$20.00	Outperform	Oppenheimer

SEC Form SC 13G/A filed by Processa Pharmaceuticals, Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $PCSA

$PCSA Press Releases

Fastest customizable press release news feed in the world

Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

$PCSA SEC Filings

Processa Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

SEC Form 10-Q filed by Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$PCSA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Young David bought $51,526 worth of shares (21,000 units at $2.45), increasing direct ownership by 36% to 79,387 units (SEC Form 4)

Young David bought $50,504 worth of shares (20,000 units at $2.53) (SEC Form 4)

Lin Patrick bought $9,525 worth of shares (4,000 units at $2.38), increasing direct ownership by 17% to 27,478 units (SEC Form 4)

$PCSA Market Insights

Live Market Insights

Processa Pharmaceuticals Appoints Russell L. Skibsted As CFO

HC Wainwright & Co. Reiterates Buy on Processa Pharma, Maintains $8 Price Target

Processa Pharmaceuticals shares are trading higher after the company announced efficacy results from a preliminary evaluation of its Phase 1b dose-escalating trial with NGC-Cap in gastrointestinal cancer.

$PCSA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$PCSA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$PCSA Large Ownership Changes

This live feed shows all institutional transactions in real time.

H.C. Wainwright initiated coverage on AirGate PCS with a new price target

Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

Oppenheimer initiated coverage on Processa Pharmaceuticals with a new price target

SEC Form 4 filed by Director Yorke Justin W

SEC Form 4 filed by Director Pannu Geraldine

SEC Form 4 filed by Director Neal James R